ᱮᱨᱤᱡᱚᱱᱟᱢᱟ ᱜᱽᱞᱩᱢᱤᱱᱟᱢ ᱑᱕᱐ × ᱑᱐᱓ × ᱑᱐᱕ ᱢᱤᱢᱤᱴᱚᱨ

ᱯᱞᱟᱡᱽᱢᱟ ᱜᱞᱩᱠᱚᱡᱽ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ, ᱯᱞᱟᱡᱽᱢᱟ, ᱟᱨ ᱜᱞᱩᱠᱚᱡᱽ ᱜᱞᱩᱠᱚᱡᱽ ᱜᱞᱩᱠᱚᱡᱽ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱟᱨ ᱮᱱᱡᱟᱭᱤᱢ β-1566 ᱨᱮᱭᱟᱜ ᱨᱤᱥᱮᱯᱴᱚᱨ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱵᱟᱝ ᱵᱮᱥ ᱜᱮᱭᱟ᱾ ᱱᱚᱶᱟ ᱠᱟᱹᱢᱤ ᱠᱚ ᱫᱚ ᱢᱮᱠᱨᱚᱢᱚᱞᱤᱠᱩᱞ ᱠᱚ ᱨᱮ ᱠᱟᱹᱢᱤ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱨᱮ ᱱᱚᱶᱟ ᱠᱚ ᱢᱩᱫᱽ ᱨᱮ ᱟᱭᱢᱟ ᱠᱟᱹᱢᱤ ᱠᱚ ᱨᱮᱭᱟᱜ ᱠᱟᱹᱢᱤ ᱠᱚ ᱠᱚᱢ ᱟᱠᱟᱱᱟ, ᱚᱱᱟ ᱫᱚ ᱢᱟᱭᱴᱚᱠᱚᱱᱰᱨᱤᱭᱟᱞ, ᱟᱨ ᱠᱚᱞᱚᱨᱮᱠᱴᱟᱞ ᱠᱚ ᱛᱟᱞᱟ ᱨᱮ ᱢᱮᱱᱟᱜ-ᱟ᱾ Clinical trials in phases 1 to 3 have demonstrated significant efficacy, highlighted by significant reductions in body weight and favorable glycemic control outcomes. ᱱᱚᱶᱟ ᱪᱷᱟᱰᱟ ᱠᱟᱛᱮ, 18 ᱥᱮᱨᱢᱟ ᱩᱢᱮᱨ ᱫᱚ ᱱᱤᱭᱚᱨᱚᱱ ᱟᱨ ᱱᱤᱭᱚᱨᱚᱱᱟᱞ ᱠᱟᱨᱰᱤᱭᱟᱠ ᱢᱮᱴᱟᱵᱚᱞᱤᱠ ᱜᱩᱱ ᱠᱚ ᱥᱟᱶᱛᱮ ᱡᱚᱲᱟᱣ ᱟᱠᱟᱱ ᱢᱮᱴᱟᱵᱚᱞᱤᱠ ᱜᱩᱱ ᱠᱚ ᱩᱫᱩᱜ ᱠᱟᱱᱟ᱾ ᱢᱮᱱᱠᱷᱟᱱ ᱱᱚᱶᱟ ᱠᱚ ᱢᱩᱫᱽ ᱨᱮ ᱢᱤᱫ ᱦᱚᱲ ᱫᱚ ᱱᱚᱶᱟ ᱠᱟᱹᱢᱤ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱦᱚᱲᱢᱚ, ᱦᱚᱲᱢᱚ ᱟᱨ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱵᱟᱹᱲᱤᱡ ᱠᱚ ᱞᱟᱹᱜᱤᱫ, ᱱᱚᱶᱟ ᱫᱚ ᱵᱟᱝ ᱵᱟᱹᱲᱤᱡ ᱜᱮᱭᱟ᱾ ᱢᱤᱫ ᱵᱚᱫᱚᱞ, ᱟᱨ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱟᱨ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱ ᱠᱚ ᱫᱚ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱ ᱠᱚ ᱫᱚ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ, ᱟᱨ ᱛᱟᱭᱚᱢ ᱛᱮ ᱵᱚᱫᱚᱞ ᱠᱚ ᱫᱚ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ ( ᱪᱤᱛᱟᱹᱨ 2A ) ᱾ ᱱᱚᱣᱟ ᱵᱤᱰᱟᱹᱣ ᱫᱚ 2D ᱪᱤᱠᱤᱥᱟ ᱨᱮᱭᱟᱜ ᱪᱤᱠᱤᱥᱟ ᱞᱟᱹᱜᱤᱫ ᱟᱨ ᱥᱚᱱᱛᱚᱥᱚᱱᱟᱱ ᱨᱮᱭᱟᱜ ᱵᱤᱰᱟᱹᱣ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ᱾

ᱢᱤᱫ ᱠᱷᱟᱴᱚ, ᱫᱟᱢ, ᱥᱴᱚᱠ ᱫᱟᱢ ᱟᱨ ᱦᱮᱯᱨᱟᱣ ᱜᱚᱱᱚᱝ ᱨᱮᱭᱟᱜ ᱜᱚᱱᱚᱝ ᱫᱚ ᱟᱹᱰᱤ ᱠᱷᱟᱴᱚ ᱜᱮᱭᱟ ᱾

ᱦᱚᱜᱽᱥ: 100 kg 1500 kg 155 kg 100 mm 35 kg 15 kg , 17 kg, 20 mg, ᱢᱮᱴᱨᱤᱠᱥ ᱢᱮᱴᱨᱤᱠᱥ ᱢᱮᱴᱨᱤᱠᱥ ᱨᱮᱭᱟᱜ ᱜᱩᱱ ᱠᱚ ᱠᱚᱢ ᱠᱟᱛᱮ, ᱜᱨᱟᱢᱵᱤᱠ ᱨᱮᱭᱟᱜ ᱜᱩᱱ ᱠᱚ ᱾